Please assess the completion status of the following clinical trial:

Trial Title: A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Current cigarette smoker~* Averages at least 10 cigarettes/day for 5 or more years~* DSM-IV diagnosis of Nicotine Dependence~* Breath carbon monoxide \> 6 ppm~* Motivated to quit: score \> 8 on Contemplation Ladder~* Age \> 18 years~Exclusion Criteria:~* Current illicit substance use~* Other tobacco use (e.g., cigar, pipe)~* History of psychosis~* Past or current cardiovascular disease~* Impaired renal functioning~* Pregnancy~* Nursing~* Current treatment for smoking cessation~* Clinically significant depressive symptoms (CES-D \> 16)~* Current suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Scheduled Gradual Reduction + Varenicline (Type: EXPERIMENTAL): Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
- Scheduled Gradual Reduction + Placebo Drug (Type: EXPERIMENTAL): Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
- Basic Advice + Varenicline (Type: EXPERIMENTAL): Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
- Basic Advice + Placebo Drug (Type: PLACEBO_COMPARATOR): Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.

Based on this trial design, predict the completion outcome and termination type (if applicable).